Marshall Wace’s Summit Therapeutics SMMT Stock Holding History

Marshall Wace’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.41M	Buy	577,190 +101,949	+21%	+$1.81M	0.01%	1103
2026 Q1	$9.01M	Buy	+475,241	New	+$7.69M	0.01%	1028
2025 Q3	–	Sell	-271,641	Closed	-$5.78M	–	3360
2025 Q2	$5.78M	Buy	+271,641	New	+$6.19M	0.01%	1071
2023 Q2	–	Sell	-214,033	Closed	-$375K	–	2933
2023 Q1	$375K	Sell	214,033 -408,833	-66%	-$1.12M	﹤0.01%	2217
2022 Q4	$2.65M	Buy	622,866 +482,206	+343%	+$877K	0.01%	1576
2022 Q3	$167K	Buy	+140,660	New	+$159K	﹤0.01%	3123

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Marshall Wace's SMMT Position: Q2 2026 in Review

Marshall Wace increased its Summit Therapeutics (SMMT) stake by 21% in Q2 2026, buying an estimated $1.81M and bringing the position to 577,190 shares worth $8.41M. The position accounts for 0.01% of the portfolio, ranked #1103.

Marshall Wace first reported a position in SMMT in Q3 2022 and has held it in 6 quarters since. The position peaked at $9.01M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Marshall Wace held 577,190 shares of Summit Therapeutics worth $8.41M as of Q2 2026.
Marshall Wace bought 101,949 Summit Therapeutics shares in Q2 2026, an estimated $1.81M.
Summit Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1103 holding.
Marshall Wace first reported a position in Summit Therapeutics in Q3 2022 and has held it in 6 quarters since.
Marshall Wace's Summit Therapeutics position peaked at $9.01M in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.